KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Profit After Tax (2017 - 2025)

Amneal Pharmaceuticals has reported Profit After Tax over the past 9 years, most recently at $35.1 million for Q4 2025.

  • Quarterly results put Profit After Tax at $35.1 million for Q4 2025, up 194.04% from a year ago — trailing twelve months through Dec 2025 was $85.2 million (up 215.4% YoY), and the annual figure for FY2025 was $72.1 million, up 197.54%.
  • Profit After Tax for Q4 2025 was $35.1 million at Amneal Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for AMRX hit a ceiling of $35.6 million in Q2 2025 and a floor of -$242.1 million in Q2 2022.
  • Median Profit After Tax over the past 5 years was $3.1 million (2022), compared with a mean of -$17.4 million.
  • Biggest five-year swings in Profit After Tax: crashed 3512.44% in 2023 and later skyrocketed 1618.59% in 2025.
  • Amneal Pharmaceuticals' Profit After Tax stood at -$27.5 million in 2021, then soared by 113.72% to $3.8 million in 2022, then crashed by 3512.44% to -$128.6 million in 2023, then soared by 109.27% to $11.9 million in 2024, then skyrocketed by 194.04% to $35.1 million in 2025.
  • The last three reported values for Profit After Tax were $35.1 million (Q4 2025), $2.4 million (Q3 2025), and $35.6 million (Q2 2025) per Business Quant data.